Immune reactivity and chronic low-grade inflammation（metaflammation） play an important role in the pathogenesis of obesity-associated metabolic disorders, including type 2 diabetes and nonalcoholic fatty liver disease（NAFLD）, a spectrum of diseases that include liver steatosis, nonalcoholic steatohepatitis（NASH）, fibrosis, and cirrhosis. Increased adiposity and insulin resistance contribute to the progression from hepatic steatosis to NASH and fibrosis through the development of proinflammatory ... 

【文章來(lái)源】：World Journal of Gastroenterology. 2016,22(44)

【文章頁(yè)數(shù)】：12 頁(yè)

【參考文獻(xiàn)】：
期刊論文
[1]Insulin resistance in development and progression of nonalcoholic fatty liver disease[J]. Shahinul Alam,Golam Mustafa,Mahabubul Alam,Nooruddin Ahmad.  World Journal of Gastrointestinal Pathophysiology. 2016(02)
[2]Non-alcoholic fatty liver disease: What the clinician needs to know[J]. Mariana Verdelho Machado,Helena Cortez-Pinto.  World Journal of Gastroenterology. 2014(36)
[3]Hepatic inflammation and progressive liver fibrosis in chronic liver disease[J]. Albert J Czaja.  World Journal of Gastroenterology. 2014(10)
[4]Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis[J]. Yoshihisa Takahashi,Yurie Soejima,Toshio Fukusato.  World Journal of Gastroenterology. 2012(19)
[5]Role of cytokines and chemokines in non-alcoholic fatty liver disease[J]. Vincent Braunersreuther,Giorgio Luciano Viviani,Franois Mach,Fabrizio Montecucco.  World Journal of Gastroenterology. 2012(08)



本文編號(hào)：3329114